StockMacro
Company, fund or insider

Help

Menu

Taysha Gene Therapies

$3.72 -33% in 6 monthsMarket cap $1.2B

TSHA on XNAS, Health Care, Taysha Gene Therapies, Inc., job postings

Measures activity, not value. Not investment advice.

Net loss of $156M over 12 months while short interest stands at 16% of shares.

  • BadRevenue down 13% to $5.5M over 12 months

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
99
Website
tayshagtx.com
Listed
Nasdaq, US
Last results
12 Nov 2026
Next results
expected around 18 Mar 2027 (an estimate: a year ago it reported on 19 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $0, net loss $39.1M.
Quarter to 31 Dec 2021: revenue –, net income -$50.4MQuarter to 31 Mar 2022: revenue –, net income -$50.1MQuarter to 30 Jun 2022: revenue –, net income -$33.9MQuarter to 30 Sep 2022: revenue –, net income -$26.3MQuarter to 31 Dec 2022: revenue –, net income -$55.7MQuarter to 31 Mar 2023: revenue $4.7M, net income -$17.6MQuarter to 31 Mar 2023: revenue $4.7M, net income -$17.6MQuarter to 30 Jun 2023: revenue $2.4M, net income -$24.6MQuarter to 30 Jun 2023: revenue $2.4M, net income -$24.6MQuarter to 30 Sep 2023: revenue $4.7M, net income -$117.1MQuarter to 30 Sep 2023: revenue $4.7M, net income -$117.1MQuarter to 31 Dec 2023: revenue $3.6M, net income $47.7MQuarter to 31 Dec 2023: revenue $3.6M, net income $47.7MQuarter to 31 Mar 2024: revenue $3.4M, net income -$24.1MQuarter to 31 Mar 2024: revenue $3.4M, net income -$24.1MQuarter to 30 Jun 2024: revenue $1.1M, net income -$20.9MQuarter to 30 Jun 2024: revenue $1.1M, net income -$20.9MQuarter to 30 Sep 2024: revenue $1.8M, net income -$25.5MQuarter to 30 Sep 2024: revenue $1.8M, net income -$25.5MQuarter to 31 Dec 2024: revenue $2.0M, net income -$18.8MQuarter to 31 Dec 2024: revenue $2.0M, net income -$18.8MQuarter to 31 Mar 2025: revenue $2.3M, net income -$21.5MQuarter to 31 Mar 2025: revenue $2.3M, net income -$21.5MQuarter to 30 Jun 2025: revenue $2.0M, net income -$26.9MQuarter to 30 Jun 2025: revenue $2.0M, net income -$26.9MQuarter to 30 Sep 2025: revenue $0, net income -$32.7MQuarter to 30 Sep 2025: revenue $0, net income -$32.7MQuarter to 31 Dec 2025: revenue $5.5M, net income -$27.9MQuarter to 31 Dec 2025: revenue $5.5M, net income -$27.9MQuarter to 31 Mar 2026: revenue $0, net income -$42.4MQuarter to 31 Mar 2026: revenue $0, net income -$42.4MQuarter to 30 Jun 2026: revenue $0, net income -$46.6MQuarter to 30 Jun 2026: revenue $0, net income -$46.6MQuarter to 30 Sep 2026: revenue $0, net income -$39.1MQuarter to 30 Sep 2026: revenue $0, net income -$39.1M
31 Dec 2021RevenueNet incomeNet losstallest bar $117.1M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$0-$39.1M
30 Jun 2026$0-$46.6M
31 Mar 2026$0-$42.4M
31 Dec 2025$5.5M-$27.9M
30 Sep 2025$0-$32.7M
30 Jun 2025$2.0M-$26.9M
31 Mar 2025$2.3M-$21.5M
31 Dec 2024$2.0M-$18.8M
30 Sep 2024$1.8M-$25.5M
30 Jun 2024$1.1M-$20.9M
31 Mar 2024$3.4M-$24.1M
31 Dec 2023$3.6M$47.7M
30 Sep 2023$4.7M-$117.1M
30 Jun 2023$2.4M-$24.6M
31 Mar 2023$4.7M-$17.6M
31 Dec 2022–-$55.7M
30 Sep 2022–-$26.3M
30 Jun 2022–-$33.9M
31 Mar 2022–-$50.1M
31 Dec 2021–-$50.4M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $5.5M $6.3M
Revenue growthRevenue of the last 12 months compared with the 12 months before. -13% +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$156.0M -$99.9M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$0.43 -$0.33
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -54.2% -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $422.8M $297.3M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $47.3M $50.9M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$375.5M (net cash) -$246.5M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.13 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $1.09
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. 221 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 153 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 3.4 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Taysha Gene TherapiesTSHA (this company) $1.2Bloss221-13%–
NovavaxNVAX $1.2Bloss3.0-61%-18.6%
Vor BiopharmaVOR $1.2B––––
Inhibrx BiosciencesINBX $1.0Bloss–––
Recursion PharmaceuticalsRXRX $1.5Bloss22.4+56%-697%
Vir BiotechnologyVIR $1.6Bloss–––

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-1.5%

203 13F filers vs 206

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

97%

316.3M shares held by 13F filers (30 Sep 2026) of 326.0M outstanding (12 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

16%

53.5M shares sold short (30 Oct 2026) of 326.0M outstanding (12 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

14.8

53.5M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+4.3%

51.2M shares sold short in the report before, 53.5M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

74%

74% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 56%

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$50K

4 quarters

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

13

13 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

13×

13 articles in the last 7 days; its usual week has 1.

Price $3.72 on 20 Nov 2026, -6.8% over 12 months (12-month range $3.51 to $6.98)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $6.7M in the last 12 months (the 12 months before: $1.1M).
Revenue per quarter. Revenue $0 in the latest quarter.
Capital spending per quarter. Capital spending $443K in the latest quarter, +310% on a year earlier.
Institutional holders (13F filers). 203 13F filers reported holding it in the latest 13F quarter, +37% on a year earlier.
Lobbying spend. Lobbying spend: $50K published in the last 12 months (none in the 12 months before).

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
19 Oct 2026Lobbying filinglobbying engagement terminated (AVIVA STRATEGIES (FKA MGB CONSULTING))
17 Feb 2026Sharp changeMany funds opening a new position: many funds opening a new position, 56 vs usual 26 (2025-12-31); 2.5x the same period a year earlier
11 Dec 2025Lobbying filingnew lobbying registration (AVIVA STRATEGIES (FKA MGB CONSULTING))
12 Aug 2025Sharp changeShort interest spike: short interest spike, 38.2M vs usual 23.6M (2025-07-31); 1.6x the same period a year earlier
29 Jul 2025Sharp changeShort interest spike: short interest spike, 44.0M vs usual 23.2M (2025-07-15); 2.1x the same period a year earlier
14 Jan 2025Sharp changeShort interest spike: short interest spike, 25.9M vs usual 17.0M (2024-12-31); 1.5x the same period a year earlier
5 Mar 2024Sharp changeShort interest spike: short interest spike, 16.3M vs usual 2.5M (2024-02-15); 7.3x the same period a year earlier
13 Feb 2024Sharp changeShort interest spike: short interest spike, 16.8M vs usual 2.3M (2024-01-31); 7.7x the same period a year earlier
30 Jan 2024Sharp changeShort interest spike: short interest spike, 17.5M vs usual 2.2M (2024-01-12); 10.2x the same period a year earlier
16 Jan 2024Sharp changeShort interest spike: short interest spike, 17.5M vs usual 2.1M (2023-12-29); 12.8x the same period a year earlier
2 Jan 2024Sharp changeShort interest spike: short interest spike, 17.1M vs usual 1.8M (2023-12-15); 18.5x the same period a year earlier
20 Dec 20238-K and other filingsDirector or officer change
12 Dec 2023Sharp changeShort interest spike: short interest spike, 16.2M vs usual 1.7M (2023-11-30); 19.6x the same period a year earlier
28 Nov 2023Sharp changeShort interest spike: short interest spike, 14.0M vs usual 1.7M (2023-11-15); 10.4x the same period a year earlier
14 Nov 2023Sharp changeShort interest spike: short interest spike, 9.8M vs usual 1.7M (2023-10-31); 5.8x the same period a year earlier
1 Nov 20238-K and other filingsDirector or officer change
1 Nov 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
31 Oct 2023Sharp changeShort interest spike: short interest spike, 10.0M vs usual 1.5M (2023-10-13); 10.4x the same period a year earlier
23 Oct 2023Lobbying filinglobbying engagement terminated (ACUITY STRATEGIC PARTNERS LLC)
17 Oct 2023Sharp changeShort interest spike: short interest spike, 10.7M vs usual 1.4M (2023-09-29); 12.0x the same period a year earlier
3 Oct 2023Sharp changeShort interest spike: short interest spike, 9.9M vs usual 1.4M (2023-09-15); 10.6x the same period a year earlier
19 Sep 2023Sharp changeShort interest spike: short interest spike, 7.4M vs usual 1.3M (2023-08-31); 8.2x the same period a year earlier
25 Aug 20238-K and other filingsPrivate placement of securities (Form D)
17 Aug 2023Sharp changeClustered insider buying: clustered insider buying (4 independent filers, 4 filing(s) in 30 days, value_usd total 16.0M)
4 Aug 20238-K and other filingsDelisting notice or listing transfer
22 Jun 20238-K and other filingsDirector or officer change
6 Jun 20238-K and other filingsDirector or officer change
27 Apr 20238-K and other filingsDelisting notice or listing transfer
27 Apr 20238-K and other filingsDirector or officer change
27 Apr 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
19 Jan 20238-K and other filingsDirector or officer change
22 Dec 20228-K and other filingsDirector or officer change
22 Dec 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
7 Nov 20228-K and other filingsPrivate placement of securities (Form D)
17 May 2022Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 8.4M vs usual 534K (2022-03-31); 15.8x the same period a year earlier
5 Apr 2022Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 8.3M vs usual 292K (2021-12-31); 162.2x the same period a year earlier
5 Feb 2022Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 1.7M)
Insider net buying (open market)
Month from 1 Nov 2021: $280K published
Month from 1 Dec 2021: $529K published
Month from 1 Feb 2022: $1.7M published
Month from 1 Jul 2022: -$231K published
Month from 1 Aug 2022: -$118K published
Month from 1 Nov 2022: $3.0M published
Month from 1 May 2023: $3K published
Month from 1 Jun 2023: -$327K published
Month from 1 Jul 2023: -$61K published
Month from 1 Aug 2023: $15.9M published
Month from 1 Nov 2023: $163K published
Month from 1 Jul 2024: $3.0M published
Month from 1 Jun 2025: $2.1M published
Month from 1 Aug 2025: -$318K published
Month from 1 Sep 2025: -$646K published
Month from 1 Dec 2025: -$1.7M published
Month from 1 Jan 2026: -$2.8M published
Month from 1 Feb 2026: -$7K published
Month from 1 Apr 2026: -$892K published
Month from 1 Jul 2026: -$1.2M published
Revenue per quarter
Quarter ended 31 Mar 2023: $4.7M; public on 12 May 2023
Quarter ended 30 Jun 2023: $2.4M; public on 15 Aug 2023
Quarter ended 30 Sep 2023: $4.7M; public on 15 Nov 2023
Quarter ended 31 Dec 2023: $3.6M; public on 20 Mar 2024
Quarter ended 31 Mar 2024: $3.4M, -28% on a year earlier; public on 15 May 2024
Quarter ended 30 Jun 2024: $1.1M, -54% on a year earlier; public on 13 Aug 2024
Quarter ended 30 Sep 2024: $1.8M, -62% on a year earlier; public on 14 Nov 2024
Quarter ended 31 Dec 2024: $2.0M, -44% on a year earlier; public on 27 Feb 2025
Quarter ended 31 Mar 2025: $2.3M, -33% on a year earlier; public on 16 May 2025
Quarter ended 30 Jun 2025: $2.0M, +79% on a year earlier; public on 13 Aug 2025
Quarter ended 30 Sep 2025: $0, -100% on a year earlier; public on 5 Nov 2025
Quarter ended 31 Dec 2025: $5.5M, +171% on a year earlier; public on 20 Mar 2026
Quarter ended 31 Mar 2026: $0, -100% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $0, -100% on a year earlier; public on 12 Aug 2026
Quarter ended 30 Sep 2026: $0; public on 13 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $8.3M, +16116% on a year earlier; public on 1 Apr 2022
Quarter ended 31 Mar 2022: $8.4M, +1478% on a year earlier; public on 17 May 2022
Quarter ended 30 Jun 2022: $7.9M, +162% on a year earlier; public on 12 Aug 2022
Quarter ended 30 Sep 2022: $2.0M, -42% on a year earlier; public on 9 Nov 2022
Quarter ended 31 Dec 2022: $2.3M, -72% on a year earlier; public on 29 Mar 2023
Quarter ended 31 Mar 2023: $3.9M, -54% on a year earlier; public on 12 May 2023
Quarter ended 31 Dec 2023: $17K, -99% on a year earlier; public on 20 Mar 2024
Quarter ended 31 Mar 2024: $140K, -96% on a year earlier; public on 15 May 2024
Quarter ended 30 Jun 2024: $201K; public on 13 Aug 2024
Quarter ended 30 Sep 2024: $35K; public on 14 Nov 2024
Quarter ended 31 Mar 2025: $378K, +170% on a year earlier; public on 7 May 2026
Quarter ended 30 Sep 2025: $108K, +209% on a year earlier; public on 5 Nov 2025
Quarter ended 31 Dec 2025: $250K; public on 20 Mar 2026
Quarter ended 31 Mar 2026: $24K, -94% on a year earlier; public on 7 May 2026
Quarter ended 30 Sep 2026: $443K, +310% on a year earlier; public on 13 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 57; public on 14 Feb 2022
31 Mar 2022 report: 67; public on 16 May 2022
30 Jun 2022 report: 56; public on 15 Aug 2022
30 Sep 2022 report: 51; public on 14 Nov 2022
31 Dec 2022 report: 51; public on 14 Feb 2023
31 Mar 2023 report: 42; public on 15 May 2023
30 Jun 2023 report: 37; public on 14 Aug 2023
30 Sep 2023 report: 60; public on 14 Nov 2023
31 Dec 2023 report: 82; public on 14 Feb 2024
31 Mar 2024 report: 106; public on 15 May 2024
30 Jun 2024 report: 102; public on 14 Aug 2024
30 Sep 2024 report: 115; public on 14 Nov 2024
31 Dec 2024 report: 126; public on 14 Feb 2025
31 Mar 2025 report: 124; public on 15 May 2025
30 Jun 2025 report: 143; public on 14 Aug 2025
30 Sep 2025 report: 148; public on 14 Nov 2025
31 Dec 2025 report: 188; public on 17 Feb 2026
31 Mar 2026 report: 187; public on 15 May 2026
30 Jun 2026 report: 206; public on 14 Aug 2026
30 Sep 2026 report: 203; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2022: $10K published
Quarter from 1 Apr 2022: $10K published
Quarter from 1 Jul 2022: $10K published
Quarter from 1 Oct 2022: $10K published
Quarter from 1 Jan 2023: $10K published
Quarter from 1 Apr 2023: $10K published
Quarter from 1 Jul 2023: $10K published
Quarter from 1 Jan 2026: $10K published
Quarter from 1 Jul 2026: $20K published
Quarter from 1 Oct 2026: $20K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market selling (USD, Form 4) at $1.2M (10 Jul 2026), 6.3× its normal reading; higher than 90% of its own history.
  • Insider net buying (open market): Insiders sold a net $6.7M in the last 12 months (the 12 months before: $1.1M).
  • Revenue per quarter: Revenue $0 in the latest quarter.
  • Capital spending per quarter: Capital spending $443K in the latest quarter, +310% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 38 insider trades

No trades in the last 90 days; the latest was filed 10 Jul 2026. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
10 Jul 2026Sukumar NagendranPresident and Head of R&DSellplanned in advance (10b5-1)200,000$6.24$1.2MForm 4
13 Apr 2026Sukumar NagendranPresident and Head of R&DSellplanned in advance (10b5-1); after exercising options200,000$4.46$892KForm 4
6 Feb 2026Kamran AlamCHIEF FINANCIAL OFFICERSell1,655$4.52$7KForm 4
27 Jan 2026Sukumar NagendranPresident and Head of R&DSell116,050$4.72$547KForm 4
27 Jan 2026Sean P. NolanChief Executive OfficerSell178,101$4.72$840KForm 4
27 Jan 2026Kamran AlamCHIEF FINANCIAL OFFICERSell102,817$4.72$485KForm 4
14 Jan 2026Sukumar NagendranPresident and Head of R&DSellplanned in advance (10b5-1); after exercising options200,000$4.71$942KForm 4
1 Dec 2025Sukumar NagendranPresident and Head of R&DSellafter exercising options370,172$4.58$1.7MForm 4

203 institutions reported shares at the end of Q3 2026, 97% of the shares outstanding; 23 opened a position, 24 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Ra Capital Management, L.P.30.4M9.33%$148.2M+6.9M+29%
Goldman Sachs Group Inc25.1M7.70%$122.3M+2.4M+11%
Avoro Capital Advisors LLC23.9M7.33%$116.3MNo change
BlackRock, Inc.22.7M6.95%$110.3M+2.0M+9.5%
Vestal Point Capital, LP18.0M5.53%$87.9M-1.4M-7.1%
Morgan Stanley15.7M4.82%$76.6M-765K-4.6%
RTW Investments, LP13.6M4.16%$66.0MNo change
FMR LLC (Fidelity)13.6M4.16%$66.0M+223K+1.7%
Vanguard Capital Management LLC12.5M3.85%$61.1M+61K+0.5%
State Street Corp11.4M3.49%$55.4M-41K-0.4%

Company events

All 29 company events

In 12 months: 1 major agreement. Results releases and routine reports are left out.

FiledWhat happenedSource
25 Jun 2026Signed a major agreement8-K
4 Nov 2025Signed a major agreement8-K
29 May 2025Signed a major agreement8-K
26 Jun 2024Signed a major agreement8-K
20 Dec 2023Director or officer change8-K
1 Nov 2023Director or officer change8-K
25 Aug 2023Private placement of securities (Form D)$150.0M sold of $150.0M offeredD
14 Aug 2023Signed a major agreementSame filing: sold shares privately8-K

Reported lobbying spend: $20K in Q3 2026, $20K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
31 Aug 2026EndedAviva Strategies (Fka MGB Consulting)for Taysha Gene TherapiesNot statedFiling
3 Nov 2025NewAviva Strategies (Fka MGB Consulting)for Taysha Gene TherapiesHealth insurance reform, affordability of medicines, biotech innovationHealth issuesFiling
1 Jul 2023EndedAcuity Strategic Partners LLCfor Taysha Gene TherapiesNot statedFiling
15 Oct 2020NewAcuity Strategic Partners LLCfor Taysha Gene TherapiesMedicare reimbursement, CURES 2.0,Health issues, Medicare/MedicaidFiling

The 5 newest of 83 articles that name the company.

Timeline

Timeline

Changes and notable records, by the date each became public

  1. 19 Oct 2026Lobbying record

    TAYSHA GENE THERAPIES: lobbying engagement terminated (AVIVA STRATEGIES (FKA MGB CONSULTING)) (dated 31 Aug 2026)

  2. 17 Feb 2026Institutional holdings change

    saw 56 13F filers open a new position in the quarter ended 31 Dec 2025, 2.5× the same quarter last year.

    Same quarter last year: 22; its normal quarter is 26.

    See the evidence
    This period
    56 (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    26
    Typical spread (median absolute deviation)
    3.5
    How far from its usual level
    +5.8
    Same quarter last year
    22
    History used
    1,918 days
    2023-12-31: 252024-03-31: 332024-06-30: 312024-09-30: 272024-12-31: 222025-03-31: 232025-06-30: 412025-09-30: 242025-12-31: 56
    the quarter ended 31 Dec 20258 earlier quartersnormal: 26

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  3. 11 Dec 2025Lobbying record

    TAYSHA GENE THERAPIES: new lobbying registration (AVIVA STRATEGIES (FKA MGB CONSULTING)) (dated 3 Nov 2025)

  4. 12 Aug 2025Short interest and volume change

    had 38.2M shares sold short in the 31 Jul 2025 report, 1.6× the same report last year.

    Same report last year: 23.2M; its normal report is 23.6M.

    See the evidence
    This period
    38.2M (the 31 Jul 2025 report)
    Normal report (median of 24 earlier)
    23.6M
    Typical spread (median absolute deviation)
    2.6M
    How far from its usual level
    +3.8
    Same report last year
    23.2M
    History used
    1,765 days
    2024-07-31: 23.2M2024-08-15: 20.8M2024-08-30: 21.7M2024-09-13: 19.8M2024-09-30: 20.6M2024-10-15: 20.7M2024-10-31: 17.6M2024-11-15: 15.8M2024-11-29: 15.7M2024-12-13: 21.9M2024-12-31: 25.9M2025-01-15: 23.9M2025-01-31: 24.1M2025-02-14: 25.1M2025-02-28: 25.5M2025-03-14: 25.2M2025-03-31: 21.6M2025-04-15: 23.1M2025-04-30: 26.1M2025-05-15: 26.2M2025-05-30: 32.0M2025-06-13: 33.3M2025-06-30: 39.9M2025-07-15: 44.0M2025-07-31: 38.2M
    the 31 Jul 2025 report24 earlier reportsnormal: 23.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  5. 25 Jul 2025Short interest and volume change

    had 44.0M shares sold short in the 15 Jul 2025 report, 2.1× the same report last year.

    Same report last year: 20.8M; its normal report is 23.2M.

    See the evidence
    This period
    44.0M (the 15 Jul 2025 report)
    Normal report (median of 24 earlier)
    23.2M
    Typical spread (median absolute deviation)
    2.4M
    How far from its usual level
    +5.8
    Same report last year
    20.8M
    History used
    1,749 days
    2024-07-15: 20.8M2024-07-31: 23.2M2024-08-15: 20.8M2024-08-30: 21.7M2024-09-13: 19.8M2024-09-30: 20.6M2024-10-15: 20.7M2024-10-31: 17.6M2024-11-15: 15.8M2024-11-29: 15.7M2024-12-13: 21.9M2024-12-31: 25.9M2025-01-15: 23.9M2025-01-31: 24.1M2025-02-14: 25.1M2025-02-28: 25.5M2025-03-14: 25.2M2025-03-31: 21.6M2025-04-15: 23.1M2025-04-30: 26.1M2025-05-15: 26.2M2025-05-30: 32.0M2025-06-13: 33.3M2025-06-30: 39.9M2025-07-15: 44.0M
    the 15 Jul 2025 report24 earlier reportsnormal: 23.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  6. 4 Jun 2025Insiders record

    Manning Paul B (ten percent owner) bought 750,000 shares of TSHA ($2.1M) (dated 3 Jun 2025)

  7. 14 Jan 2025Short interest and volume change

    had 25.9M shares sold short in the 31 Dec 2024 report, 1.5× the same report last year.

    Same report last year: 17.5M; its normal report is 17.0M.

    See the evidence
    This period
    25.9M (the 31 Dec 2024 report)
    Normal report (median of 24 earlier)
    17.0M
    Typical spread (median absolute deviation)
    1.3M
    How far from its usual level
    +4.6
    Same report last year
    17.5M
    History used
    1,553 days
    2023-12-29: 17.5M2024-01-12: 17.5M2024-01-31: 16.8M2024-02-15: 16.3M2024-02-29: 13.9M2024-03-15: 15.8M2024-03-28: 17.0M2024-04-15: 16.1M2024-04-30: 16.9M2024-05-15: 17.0M2024-05-31: 16.1M2024-06-14: 14.7M2024-06-28: 13.5M2024-07-15: 20.8M2024-07-31: 23.2M2024-08-15: 20.8M2024-08-30: 21.7M2024-09-13: 19.8M2024-09-30: 20.6M2024-10-15: 20.7M2024-10-31: 17.6M2024-11-15: 15.8M2024-11-29: 15.7M2024-12-13: 21.9M2024-12-31: 25.9M
    the 31 Dec 2024 report24 earlier reportsnormal: 17.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  8. 2 Jul 2024Insiders record

    Manning Paul B (ten percent owner) bought 1,333,333 shares of TSHA ($3.0M) (dated 1 Jul 2024)

  9. 28 Feb 2024Short interest and volume change

    had 16.3M shares sold short in the 15 Feb 2024 report, 7.3× the same report last year.

    Same report last year: 2.2M; its normal report is 2.5M.

    See the evidence
    This period
    16.3M (the 15 Feb 2024 report)
    Normal report (median of 24 earlier)
    2.5M
    Typical spread (median absolute deviation)
    1.6M
    How far from its usual level
    +5.8
    Same report last year
    2.2M
    History used
    1,233 days
    2023-02-15: 2.2M2023-02-28: 2.7M2023-03-15: 2.4M2023-03-31: 1.9M2023-04-14: 1.6M2023-04-28: 1.7M2023-05-15: 1.2M2023-05-31: 1.2M2023-06-15: 1.4M2023-06-30: 1.3M2023-07-14: 1.1M2023-07-31: 1.1M2023-08-15: 734K2023-08-31: 7.4M2023-09-15: 9.9M2023-09-29: 10.7M2023-10-13: 10.0M2023-10-31: 9.8M2023-11-15: 14.0M2023-11-30: 16.2M2023-12-15: 17.1M2023-12-29: 17.5M2024-01-12: 17.5M2024-01-31: 16.8M2024-02-15: 16.3M
    the 15 Feb 2024 report24 earlier reportsnormal: 2.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  10. 10 Feb 2024Short interest and volume change

    had 16.8M shares sold short in the 31 Jan 2024 report, 7.7× the same report last year.

    Same report last year: 2.2M; its normal report is 2.3M.

    See the evidence
    This period
    16.8M (the 31 Jan 2024 report)
    Normal report (median of 24 earlier)
    2.3M
    Typical spread (median absolute deviation)
    1.2M
    How far from its usual level
    +8.2
    Same report last year
    2.2M
    History used
    1,218 days
    2023-01-31: 2.2M2023-02-15: 2.2M2023-02-28: 2.7M2023-03-15: 2.4M2023-03-31: 1.9M2023-04-14: 1.6M2023-04-28: 1.7M2023-05-15: 1.2M2023-05-31: 1.2M2023-06-15: 1.4M2023-06-30: 1.3M2023-07-14: 1.1M2023-07-31: 1.1M2023-08-15: 734K2023-08-31: 7.4M2023-09-15: 9.9M2023-09-29: 10.7M2023-10-13: 10.0M2023-10-31: 9.8M2023-11-15: 14.0M2023-11-30: 16.2M2023-12-15: 17.1M2023-12-29: 17.5M2024-01-12: 17.5M2024-01-31: 16.8M
    the 31 Jan 2024 report24 earlier reportsnormal: 2.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  11. 25 Jan 2024Short interest and volume change

    had 17.5M shares sold short in the 12 Jan 2024 report, 10× the same report last year.

    Same report last year: 1.7M; its normal report is 2.2M.

    See the evidence
    This period
    17.5M (the 12 Jan 2024 report)
    Normal report (median of 24 earlier)
    2.2M
    Typical spread (median absolute deviation)
    1.1M
    How far from its usual level
    +9.8
    Same report last year
    1.7M
    History used
    1,199 days
    2023-01-13: 1.7M2023-01-31: 2.2M2023-02-15: 2.2M2023-02-28: 2.7M2023-03-15: 2.4M2023-03-31: 1.9M2023-04-14: 1.6M2023-04-28: 1.7M2023-05-15: 1.2M2023-05-31: 1.2M2023-06-15: 1.4M2023-06-30: 1.3M2023-07-14: 1.1M2023-07-31: 1.1M2023-08-15: 734K2023-08-31: 7.4M2023-09-15: 9.9M2023-09-29: 10.7M2023-10-13: 10.0M2023-10-31: 9.8M2023-11-15: 14.0M2023-11-30: 16.2M2023-12-15: 17.1M2023-12-29: 17.5M2024-01-12: 17.5M
    the 12 Jan 2024 report24 earlier reportsnormal: 2.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  12. 11 Jan 2024Short interest and volume change

    had 17.5M shares sold short in the 29 Dec 2023 report, 13× the same report last year.

    Same report last year: 1.4M; its normal report is 2.1M.

    See the evidence
    This period
    17.5M (the 29 Dec 2023 report)
    Normal report (median of 24 earlier)
    2.1M
    Typical spread (median absolute deviation)
    846K
    How far from its usual level
    +12.3
    Same report last year
    1.4M
    History used
    1,185 days
    2022-12-30: 1.4M2023-01-13: 1.7M2023-01-31: 2.2M2023-02-15: 2.2M2023-02-28: 2.7M2023-03-15: 2.4M2023-03-31: 1.9M2023-04-14: 1.6M2023-04-28: 1.7M2023-05-15: 1.2M2023-05-31: 1.2M2023-06-15: 1.4M2023-06-30: 1.3M2023-07-14: 1.1M2023-07-31: 1.1M2023-08-15: 734K2023-08-31: 7.4M2023-09-15: 9.9M2023-09-29: 10.7M2023-10-13: 10.0M2023-10-31: 9.8M2023-11-15: 14.0M2023-11-30: 16.2M2023-12-15: 17.1M2023-12-29: 17.5M
    the 29 Dec 2023 report24 earlier reportsnormal: 2.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  13. 28 Dec 2023Short interest and volume change

    had 17.1M shares sold short in the 15 Dec 2023 report, 19× the same report last year.

    Same report last year: 926K; its normal report is 1.8M.

    See the evidence
    This period
    17.1M (the 15 Dec 2023 report)
    Normal report (median of 24 earlier)
    1.8M
    Typical spread (median absolute deviation)
    670K
    How far from its usual level
    +15.4
    Same report last year
    926K
    History used
    1,171 days
    2022-12-15: 926K2022-12-30: 1.4M2023-01-13: 1.7M2023-01-31: 2.2M2023-02-15: 2.2M2023-02-28: 2.7M2023-03-15: 2.4M2023-03-31: 1.9M2023-04-14: 1.6M2023-04-28: 1.7M2023-05-15: 1.2M2023-05-31: 1.2M2023-06-15: 1.4M2023-06-30: 1.3M2023-07-14: 1.1M2023-07-31: 1.1M2023-08-15: 734K2023-08-31: 7.4M2023-09-15: 9.9M2023-09-29: 10.7M2023-10-13: 10.0M2023-10-31: 9.8M2023-11-15: 14.0M2023-11-30: 16.2M2023-12-15: 17.1M
    the 15 Dec 2023 report24 earlier reportsnormal: 1.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  14. 20 Dec 2023Filings record

    Director or officer change

  15. 12 Dec 2023Short interest and volume change

    had 16.2M shares sold short in the 30 Nov 2023 report, 20× the same report last year.

    Same report last year: 824K; its normal report is 1.7M.

    See the evidence
    This period
    16.2M (the 30 Nov 2023 report)
    Normal report (median of 24 earlier)
    1.7M
    Typical spread (median absolute deviation)
    611K
    How far from its usual level
    +15.9
    Same report last year
    824K
    History used
    1,156 days
    2022-11-30: 824K2022-12-15: 926K2022-12-30: 1.4M2023-01-13: 1.7M2023-01-31: 2.2M2023-02-15: 2.2M2023-02-28: 2.7M2023-03-15: 2.4M2023-03-31: 1.9M2023-04-14: 1.6M2023-04-28: 1.7M2023-05-15: 1.2M2023-05-31: 1.2M2023-06-15: 1.4M2023-06-30: 1.3M2023-07-14: 1.1M2023-07-31: 1.1M2023-08-15: 734K2023-08-31: 7.4M2023-09-15: 9.9M2023-09-29: 10.7M2023-10-13: 10.0M2023-10-31: 9.8M2023-11-15: 14.0M2023-11-30: 16.2M
    the 30 Nov 2023 report24 earlier reportsnormal: 1.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  16. 28 Nov 2023Short interest and volume change

    had 14.0M shares sold short in the 15 Nov 2023 report, 10× the same report last year.

    Same report last year: 1.3M; its normal report is 1.7M.

    See the evidence
    This period
    14.0M (the 15 Nov 2023 report)
    Normal report (median of 24 earlier)
    1.7M
    Typical spread (median absolute deviation)
    556K
    How far from its usual level
    +14.9
    Same report last year
    1.3M
    History used
    1,141 days
    2022-11-15: 1.3M2022-11-30: 824K2022-12-15: 926K2022-12-30: 1.4M2023-01-13: 1.7M2023-01-31: 2.2M2023-02-15: 2.2M2023-02-28: 2.7M2023-03-15: 2.4M2023-03-31: 1.9M2023-04-14: 1.6M2023-04-28: 1.7M2023-05-15: 1.2M2023-05-31: 1.2M2023-06-15: 1.4M2023-06-30: 1.3M2023-07-14: 1.1M2023-07-31: 1.1M2023-08-15: 734K2023-08-31: 7.4M2023-09-15: 9.9M2023-09-29: 10.7M2023-10-13: 10.0M2023-10-31: 9.8M2023-11-15: 14.0M
    the 15 Nov 2023 report24 earlier reportsnormal: 1.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  17. 21 Nov 2023Insiders record

    Manning Paul B (ten percent owner) bought 100,000 shares of TSHA ($163,000) (dated 20 Nov 2023)

  18. 10 Nov 2023Short interest and volume change

    had 9.8M shares sold short in the 31 Oct 2023 report, 5.8× the same report last year.

    Same report last year: 1.7M; its normal report is 1.7M.

    See the evidence
    This period
    9.8M (the 31 Oct 2023 report)
    Normal report (median of 24 earlier)
    1.7M
    Typical spread (median absolute deviation)
    528K
    How far from its usual level
    +10.4
    Same report last year
    1.7M
    History used
    1,126 days
    2022-10-31: 1.7M2022-11-15: 1.3M2022-11-30: 824K2022-12-15: 926K2022-12-30: 1.4M2023-01-13: 1.7M2023-01-31: 2.2M2023-02-15: 2.2M2023-02-28: 2.7M2023-03-15: 2.4M2023-03-31: 1.9M2023-04-14: 1.6M2023-04-28: 1.7M2023-05-15: 1.2M2023-05-31: 1.2M2023-06-15: 1.4M2023-06-30: 1.3M2023-07-14: 1.1M2023-07-31: 1.1M2023-08-15: 734K2023-08-31: 7.4M2023-09-15: 9.9M2023-09-29: 10.7M2023-10-13: 10.0M2023-10-31: 9.8M
    the 31 Oct 2023 report24 earlier reportsnormal: 1.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  19. 1 Nov 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  20. 1 Nov 2023Filings record

    Director or officer change

  21. 25 Oct 2023Short interest and volume change

    had 10.0M shares sold short in the 13 Oct 2023 report, 10× the same report last year.

    Same report last year: 961K; its normal report is 1.5M.

    See the evidence
    This period
    10.0M (the 13 Oct 2023 report)
    Normal report (median of 24 earlier)
    1.5M
    Typical spread (median absolute deviation)
    419K
    How far from its usual level
    +13.7
    Same report last year
    961K
    History used
    1,108 days
    2022-10-14: 961K2022-10-31: 1.7M2022-11-15: 1.3M2022-11-30: 824K2022-12-15: 926K2022-12-30: 1.4M2023-01-13: 1.7M2023-01-31: 2.2M2023-02-15: 2.2M2023-02-28: 2.7M2023-03-15: 2.4M2023-03-31: 1.9M2023-04-14: 1.6M2023-04-28: 1.7M2023-05-15: 1.2M2023-05-31: 1.2M2023-06-15: 1.4M2023-06-30: 1.3M2023-07-14: 1.1M2023-07-31: 1.1M2023-08-15: 734K2023-08-31: 7.4M2023-09-15: 9.9M2023-09-29: 10.7M2023-10-13: 10.0M
    the 13 Oct 2023 report24 earlier reportsnormal: 1.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  22. 23 Oct 2023Lobbying record

    TAYSHA GENE THERAPIES: lobbying engagement terminated (ACUITY STRATEGIC PARTNERS LLC) (dated 1 Jul 2023)

  23. 12 Oct 2023Short interest and volume change

    had 10.7M shares sold short in the 29 Sep 2023 report, 12× the same report last year.

    Same report last year: 890K; its normal report is 1.4M.

    See the evidence
    This period
    10.7M (the 29 Sep 2023 report)
    Normal report (median of 24 earlier)
    1.4M
    Typical spread (median absolute deviation)
    382K
    How far from its usual level
    +16.4
    Same report last year
    890K
    History used
    1,094 days
    2022-09-30: 890K2022-10-14: 961K2022-10-31: 1.7M2022-11-15: 1.3M2022-11-30: 824K2022-12-15: 926K2022-12-30: 1.4M2023-01-13: 1.7M2023-01-31: 2.2M2023-02-15: 2.2M2023-02-28: 2.7M2023-03-15: 2.4M2023-03-31: 1.9M2023-04-14: 1.6M2023-04-28: 1.7M2023-05-15: 1.2M2023-05-31: 1.2M2023-06-15: 1.4M2023-06-30: 1.3M2023-07-14: 1.1M2023-07-31: 1.1M2023-08-15: 734K2023-08-31: 7.4M2023-09-15: 9.9M2023-09-29: 10.7M
    the 29 Sep 2023 report24 earlier reportsnormal: 1.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  24. 27 Sep 2023Short interest and volume change

    had 9.9M shares sold short in the 15 Sep 2023 report, 11× the same report last year.

    Same report last year: 939K; its normal report is 1.4M.

    See the evidence
    This period
    9.9M (the 15 Sep 2023 report)
    Normal report (median of 24 earlier)
    1.4M
    Typical spread (median absolute deviation)
    382K
    How far from its usual level
    +15.1
    Same report last year
    939K
    History used
    1,080 days
    2022-09-15: 939K2022-09-30: 890K2022-10-14: 961K2022-10-31: 1.7M2022-11-15: 1.3M2022-11-30: 824K2022-12-15: 926K2022-12-30: 1.4M2023-01-13: 1.7M2023-01-31: 2.2M2023-02-15: 2.2M2023-02-28: 2.7M2023-03-15: 2.4M2023-03-31: 1.9M2023-04-14: 1.6M2023-04-28: 1.7M2023-05-15: 1.2M2023-05-31: 1.2M2023-06-15: 1.4M2023-06-30: 1.3M2023-07-14: 1.1M2023-07-31: 1.1M2023-08-15: 734K2023-08-31: 7.4M2023-09-15: 9.9M
    the 15 Sep 2023 report24 earlier reportsnormal: 1.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  25. 13 Sep 2023Short interest and volume change

    had 7.4M shares sold short in the 31 Aug 2023 report, 8.2× the same report last year.

    Same report last year: 893K; its normal report is 1.3M.

    See the evidence
    This period
    7.4M (the 31 Aug 2023 report)
    Normal report (median of 24 earlier)
    1.3M
    Typical spread (median absolute deviation)
    378K
    How far from its usual level
    +10.8
    Same report last year
    893K
    History used
    1,065 days
    2022-08-31: 893K2022-09-15: 939K2022-09-30: 890K2022-10-14: 961K2022-10-31: 1.7M2022-11-15: 1.3M2022-11-30: 824K2022-12-15: 926K2022-12-30: 1.4M2023-01-13: 1.7M2023-01-31: 2.2M2023-02-15: 2.2M2023-02-28: 2.7M2023-03-15: 2.4M2023-03-31: 1.9M2023-04-14: 1.6M2023-04-28: 1.7M2023-05-15: 1.2M2023-05-31: 1.2M2023-06-15: 1.4M2023-06-30: 1.3M2023-07-14: 1.1M2023-07-31: 1.1M2023-08-15: 734K2023-08-31: 7.4M
    the 31 Aug 2023 report24 earlier reportsnormal: 1.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  26. 25 Aug 2023Filings record

    Private placement of securities (Form D)

  27. 17 Aug 2023Insiders change

    had 4 insiders buy $16.0M of its shares on the open market within 30 days (4 filings).

    Who bought: Nolan Sean P., Manning Paul B, Stalfort John A III, Donenberg Phillip B..

    See the evidence (4 source records)
    Independent buyers
    4
    Purchase filings (Form 4, code P)
    4
    Total bought
    $16.0M
    Window
    18 Jul 2023 to 17 Aug 2023

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  28. 17 Aug 2023Insiders record

    Donenberg Phillip B. (director) bought 111,111 shares of TSHA ($100,000) (dated 16 Aug 2023)

  29. 17 Aug 2023Insiders record

    Stalfort John A III (director) bought 777,778 shares of TSHA ($700,000) (dated 16 Aug 2023)

  30. 17 Aug 2023Insiders record

    Manning Paul B (ten percent owner) bought 16,466,667 shares of TSHA ($14.8M) (dated 16 Aug 2023)

  31. 17 Aug 2023Insiders record

    Nolan Sean P. (Chief Executive Officer) bought 444,444 shares of TSHA ($400,000) (dated 16 Aug 2023)

  32. 4 Aug 2023Filings record

    Delisting notice or listing transfer

  33. 22 Jun 2023Filings record

    Director or officer change

  34. 6 Jun 2023Filings record

    Director or officer change

  35. 19 May 2023Insiders record

    Nagendran Sukumar (President and Head of R&D) bought 5,000 shares of TSHA ($3,400) (dated 18 May 2023)

  36. 27 Apr 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  37. 27 Apr 2023Filings record

    Director or officer change

  38. 27 Apr 2023Filings record

    Delisting notice or listing transfer

  39. 19 Jan 2023Filings record

    Director or officer change

  40. 22 Dec 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

Showing the newest 40 of 65 entries; narrow the window or the kind of data to see older ones.

Not listed: 118 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001806310
Ticker
TSHA
Domain
tayshagtx.com
Hq location
TX|DALLAS|75247 (1 unverified)
Lobbying client
taysha gene therapies
Name
Taysha Gene Therapies, Inc.
  • Federal lobbying disclosures (LDA)4 records, 46 data points15 Oct 2020 to 30 Sep 2026
  • SEC Form 13F institutional holdings225 data points30 Sep 2020 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)116 records1 May 2020 to 12 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)379 data points20 Sep 2019 to 12 Nov 2026
  • SEC Form 4 insider transactions38 records, 124 data points17 May 2021 to 10 Jul 2026
  • FINRA short interest (twice monthly)437 data points30 Sep 2020 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)3096 data points24 Sep 2020 to 20 Nov 2026